Introduction Late-onset multiple sclerosis (LOMS) now comprises over 10% of MS diagnoses in contemporary cohorts. The effectiveness of disease-modifying therapies (DMTs) in LOMS is unclear. We aimed t...

Multiple sclerosis (MS) is the most common neurological disorder in yo...

Background In multiple sclerosis (MS), inner retinal thinning measured by optical coherence tomography (OCT) is related to lesional and gray matter changes of the brain. Objective To evaluate the asso...

This study aimed to assess the perceptions of neurologists in Australia and New Zealand regarding climate change and its impact on neurological practi…

Background Natalizumab is a highly effective drug for patients with relapsing-remitting multiple sclerosis (MS). A disadvantage of this treatment is the risk of progressive multifocal leukoencephalopa...

Background Cognitive impairment is one of the most common and debilitating symptoms of relapsing–remitting multiple sclerosis (RRMS). Digital cognitive biomarkers require less time and resources and...

Get involved in RACP Policy and Advocacy and make a valuable contribution to the RACP, your profession, and the community

A safe, effective and comprehensive approach to managing MS is crucial for improving long term outcomes and quality of life in individuals affected by MS

High‐efficacy (HE) disease‐modifying therapies (DMT) are increasingly used to treat multiple sclerosis (MS). Concerns arise when considering the decreasing efficacy and increasing risk of adverse even...

Autologous haematopoietic stem cell transplantation (AHSCT) is a treatment option for some forms of multiple sclerosis (MS), but uncertainties remain about its implementation in clinical practice and ...

Background Upper limb dysfunction is a common debilitating feature of relapsing-remitting multiple sclerosis (RRMS). We aimed to examine the longitudinal trajectory of the iPad®-based Manual Dexteri.....

This randomized clinical trial investigates whether first-line disease-modifying therapy can be safely discontinued in patients with long-term stable multiple sclerosis.

In older pwMS, ocrelizumab effectively reduced relapses compared with IFN/GA. Overall relapse activity was low. This study adds valuable real-world data for informed DMT decision making with older pwM...

Multiple Sclerosis (MS) represents a neuroinflammatory autoimmune disease characterized by the predominance of circulating T cell subsets with proinfl…

Subscription and open access journals from Sage, the world's leading independent academic publisher.

COVID-19 infection was associated with a significantly increased MS relapse rate and a shorter time to first relapse. There was no effect on confirmed EDSS progression over the short term. These resul...